



Advice. Expertise. Services.

Your partner for preclinical
studies in oncology



In-vitro services



In-vivo services



Ex-vivo services



Optimize and accelerate the preclinical stages of your drug development strategy

IN-VITRO



Determination of IC50 / EC50 and synergy

- MTT
- MTS
- Cell Titer-Glo®

Continuous monitoring studies

- IncuCyte®
- xCELLigence™

Characterisation of samples

- Quantitative PCR
- Western Blotting
- ELISA assays
- Immunoprecipitation
- Flow cytometry studies


Immunology services

- T cell based assays
- Myeloid cells based assays
- ADCC assays with fresh NK cells
- ADCP assays with fresh myeloid cells


Development of immunotherapies

- Highlight the target and decipher the mechanisms of action of therapeutic antibodies

EX-VIVO



IN-VIVO



Identification of the best models / Choice of the most efficient candidate / Assessment of efficacy at lower costs

- Antitumor efficacy studies : **150 CDX and 40 syngeneic mice models**
- Systemic and haematological toxicity of your compounds in rodents
- Pharmacokinetics properties in mouse and rat
- Orthotopic models
- Secondary resistances to reference therapies

SECONDARY RESISTANCES TO REFERENCES THERAPIES

CDX Models

Lymphoma

Follicular Lymphoma - (RL model):
• Rituximab / GA101 / R-CHOP / R-DHAP)

Mantle Cells Lymphoma - (Granta model):
• Rituximab

Diffuse large B cells lymphoma - (Toledo model):
• Rituximab

Burkitt's lymphoma
• Raji model: Rituximab
• Daudi model: CAL-101

Myeloma


Plasma cells myeloma RPMI8226 model
• Daratumumab

Multiple myeloma MM.1S
• Daratumumab

Breast

Tubular Adenocarcinoma BT474
• T-DM1

MDA-MB-361 model
• Trastuzumab T-DM1




Bespoke services : On demand
development of resistant models
(Syngeneic or CDX models)

Syngeneic Models

IVIS® Lumina Series III Imager

NEW



MDA-MB-231 cell line

1.
IN-VIVO AND 3D IMAGING OF THE
TUMORS / METASTASES

2.
PRECISE TUMOR MONITORING
AND FOLLOW-UP

3.
BIODISTRIBUTION AND
EFFICACY STUDIES





- 1** The **reactivity, adaptability** and **flexibility** of a human-sized compagny
- 2** A **Scientific Advisory Board** of clinical experts
- 3** An exceptional access to **cutting-edge technologies, equipments** and **animal facilities**



To learn more about Antineo's models and services, please contact us:

 (+33) 4 72 36 15 71

 www.antineo.fr

 BIOPARC ROCKEFELLER
BATIMENT BIOSERRA 2
2E ETAGE - 60F AVENUE ROCKEFELLER
69008 LYON

 [Antineo](https://www.linkedin.com/company/antineo)



Marie TAUTOU, PhD

Study Director

Head of Business Development

marie.tautou@antineo.fr



Renaud SIDGWICK

Chief Executive Officer